|
?:abstract
|
-
In 2019 later, the coronavirus disease 2019(COVID-19)pandemic have killed more than 1 million people worldwide. SARS-CoV2 cause severe pneumonia, the mortality is higher in cancer patients. Moreover, most of cancer patients are elderly and have other co-morbidities which are risk factors of COVID-19. It is still unclear that the relationship between anticancer treatments and COVID-19 are risk factors. Also, the fewer cancer diagnosis for cancer has suggested. The delay of cancer diagnosis will lead to presentation at more advanced stages and poor outcomes. Balancing the value of anticancer treatments with competing risks in COVID-19 pandemic is very difficult. The priorities for cancer care during COVID-19 pandemic affect cancer treatment decisions. However, anticancer treatments have the potential to cure should not be delayed. When treatment has been started, we need to consider the local healthcare system to triage the symptoms that is difficult to distinguish between COVID-19 and side effect of treatment, for example, febrile neutropenia and drug-induced pneumonitis. To continue cancer treatment, education of infection prevention and protection, not only for medical staff but also for patient, are very important.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}